脓毒症内型(炎症型、适应型、凝血型)在2019冠状病毒病中的验证
这项前瞻性单中心观察性队列研究纳入97例PCR确诊且胸片证实的COVID-19成人患者,入院24小时内采血,应用先前在细菌脓毒症中定义的33-mRNA分类器分为炎症型、适应型或凝血型。结果显示炎症型占29%、适应型44%、凝血型27%,与既往细菌脓毒症研究分布相似。适应型患者严重呼吸衰竭率更低且无死亡;凝血型和炎症型死亡率分别为42%和18%。凝血型D-二聚体最高,炎症型C反应蛋白和白细胞介素-6最高。
要点
- 33-mRNA分类器在COVID-19中可重现三种内型:炎症型29%、适应型44%、凝血型27%。
- 适应型患者严重呼吸衰竭率更低且无死亡;凝血型死亡率42%,炎症型18%。
- 凝血型D-二聚体最高,炎症型C反应蛋白和白细胞介素-6最高。
- 该分类器先前仅在细菌脓毒症中训练和验证,本研究为在病毒脓毒症中的验证。
- 需进一步验证内型及与免疫调节治疗的交互作用。
适用人群与场景
- 成人患者,入院24小时内,COVID-19经聚合酶链反应确诊且胸片证实。
- 单中心研究,患者 enrolled 于希腊雅典。
- 排除标准原文未提及。
诊断标准与关键阈值
- 使用先前定义的33信使RNA分类器将患者分为炎症型、适应型或凝血型。
- 严重呼吸衰竭定义原文未提及。
处置流程与药物剂量
- 原文未提及
红旗征与不能漏的情况
- 原文未提及
研究设计与关键结果
- 研究类型:前瞻性单中心观察性队列研究,样本量97例,单中心。
- 人群:成人COVID-19患者,入院24小时内,PCR确诊且胸片证实;50例进展为严重呼吸衰竭,16例死亡。
- 干预与对照:无干预,应用33-mRNA分类器分配内型。
- 主要终点结果:内型分布为炎症型29%、适应型44%、凝血型27%,与先前细菌脓毒症研究相似。
- 关键次要终点:适应型严重呼吸衰竭率更低且无死亡;凝血型和炎症型死亡率分别为42%和18%;凝血型D-二聚体最高,炎症型C反应蛋白和白细胞介素-6最高。
- 不良事件:原文未提及。
证据类型、等级与局限
- 证据类型:前瞻性单中心观察性队列研究。
- 证据等级或推荐强度:原文未提及。
- 局限:单中心、观察性设计、样本量97例;分类器先前仅在细菌脓毒症中训练和验证。
对床旁实践的改变
- 原文未提及
指南或共识出处
- 原文未提及
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: Complex critical syndromes like sepsis and coronavirus disease 2019 may be composed of underling "endotypes," which may respond differently to treatment. The aim of this study was to test whether a previously defined bacterial sepsis endotypes classifier recapitulates the same clinical and immunological endotypes in coronavirus disease 2019.
DESIGN: Prospective single-center observational cohort study.
SETTING: Patients were enrolled in Athens, Greece, and blood was shipped to Inflammatix (Burlingame, CA) for analysis.
PATIENTS: Adult patients within 24 hours of hospital admission with coronavirus disease 2019 confirmed by polymerase chain reaction and chest radiography.
INTERVENTIONS: None.
MEASUREMENTS AND MAIN RESULTS: We studied 97 patients with coronavirus disease 2019, of which 50 went on to severe respiratory failure (SRF) and 16 died. We applied a previously defined 33-messenger RNA classifier to assign endotype (Inflammopathic, Adaptive, or Coagulopathic) to each patient. We tested endotype status against other clinical parameters including laboratory values, severity scores, and outcomes. Patients were assigned as Inflammopathic (29%), Adaptive (44%), or Coagulopathic (27%), similar to our prior study in bacterial sepsis. Adaptive patients had lower rates of SRF and no deaths. Coagulopathic and Inflammopathic endotypes had 42% and 18% mortality rates, respectively. The Coagulopathic group showed highest d-dimers, and the Inflammopathic group showed highest C-reactive protein and interleukin-6 levels.
CONCLUSIONS: Our predefined 33-messenger RNA endotypes classifier recapitulated immune phenotypes in viral sepsis (coronavirus disease 2019) despite its prior training and validation only in bacterial sepsis. Further work should focus on continued validation of the endotypes and their interaction with immunomodulatory therapy.
参考来源
- Sweeney TE, Liesenfeld O, Wacker J, et al. Validation of Inflammopathic, Adaptive, and Coagulopathic Sepsis Endotypes in Coronavirus Disease 2019. Crit Care Med. 2021. PMID: 33201004. doi:10.1097/CCM.0000000000004786
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。